APLS vs. EIDX, RARX, ALXO, OMER, RIGL, ALNY, GMAB, TEVA, RPRX, and BGNE
Should you be buying Apellis Pharmaceuticals stock or one of its competitors? The main competitors of Apellis Pharmaceuticals include Eidos Therapeutics (EIDX), Ra Pharmaceuticals (RARX), ALX Oncology (ALXO), Omeros (OMER), Rigel Pharmaceuticals (RIGL), Alnylam Pharmaceuticals (ALNY), Genmab A/S (GMAB), Teva Pharmaceutical Industries (TEVA), Royalty Pharma (RPRX), and BeiGene (BGNE).
Apellis Pharmaceuticals (NASDAQ:APLS) and Eidos Therapeutics (NASDAQ:EIDX) are both mid-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, valuation, community ranking, dividends, risk, profitability, analyst recommendations, media sentiment and institutional ownership.
96.3% of Apellis Pharmaceuticals shares are owned by institutional investors. Comparatively, 31.4% of Eidos Therapeutics shares are owned by institutional investors. 6.8% of Apellis Pharmaceuticals shares are owned by insiders. Comparatively, 70.1% of Eidos Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Apellis Pharmaceuticals received 172 more outperform votes than Eidos Therapeutics when rated by MarketBeat users. Likewise, 67.23% of users gave Apellis Pharmaceuticals an outperform vote while only 63.20% of users gave Eidos Therapeutics an outperform vote.
In the previous week, Apellis Pharmaceuticals had 23 more articles in the media than Eidos Therapeutics. MarketBeat recorded 23 mentions for Apellis Pharmaceuticals and 0 mentions for Eidos Therapeutics. Apellis Pharmaceuticals' average media sentiment score of 0.63 beat Eidos Therapeutics' score of 0.00 indicating that Apellis Pharmaceuticals is being referred to more favorably in the media.
Eidos Therapeutics has lower revenue, but higher earnings than Apellis Pharmaceuticals. Eidos Therapeutics is trading at a lower price-to-earnings ratio than Apellis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Apellis Pharmaceuticals currently has a consensus price target of $74.38, indicating a potential upside of 89.49%. Given Apellis Pharmaceuticals' higher possible upside, research analysts plainly believe Apellis Pharmaceuticals is more favorable than Eidos Therapeutics.
Apellis Pharmaceuticals has a beta of 0.97, suggesting that its stock price is 3% less volatile than the S&P 500. Comparatively, Eidos Therapeutics has a beta of -0.16, suggesting that its stock price is 116% less volatile than the S&P 500.
Eidos Therapeutics has a net margin of 0.00% compared to Apellis Pharmaceuticals' net margin of -79.67%. Eidos Therapeutics' return on equity of -65.21% beat Apellis Pharmaceuticals' return on equity.
Summary
Apellis Pharmaceuticals beats Eidos Therapeutics on 12 of the 18 factors compared between the two stocks.
Get Apellis Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for APLS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding APLS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Apellis Pharmaceuticals Competitors List
Related Companies and Tools
